ATE532516T1 - Verfahren zur synthese von glyt-1-hemmern - Google Patents

Verfahren zur synthese von glyt-1-hemmern

Info

Publication number
ATE532516T1
ATE532516T1 AT08709206T AT08709206T ATE532516T1 AT E532516 T1 ATE532516 T1 AT E532516T1 AT 08709206 T AT08709206 T AT 08709206T AT 08709206 T AT08709206 T AT 08709206T AT E532516 T1 ATE532516 T1 AT E532516T1
Authority
AT
Austria
Prior art keywords
compound
formula
glyt
inhibitors
synthesis
Prior art date
Application number
AT08709206T
Other languages
English (en)
Inventor
Christophe Pfleger
Pius Waldmeier
Shaoning Wang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE532516T1 publication Critical patent/ATE532516T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT08709206T 2007-03-05 2008-02-25 Verfahren zur synthese von glyt-1-hemmern ATE532516T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07103485 2007-03-05
PCT/EP2008/052244 WO2008107334A2 (en) 2007-03-05 2008-02-25 Process for the synthesis of glyt-1 inhibitors

Publications (1)

Publication Number Publication Date
ATE532516T1 true ATE532516T1 (de) 2011-11-15

Family

ID=39469606

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08709206T ATE532516T1 (de) 2007-03-05 2008-02-25 Verfahren zur synthese von glyt-1-hemmern

Country Status (13)

Country Link
US (1) US7812161B2 (de)
EP (1) EP2131843B1 (de)
JP (1) JP4745446B2 (de)
KR (1) KR101143073B1 (de)
CN (1) CN101622000B (de)
AT (1) ATE532516T1 (de)
AU (1) AU2008223915B2 (de)
BR (1) BRPI0808570B8 (de)
CA (1) CA2678630C (de)
ES (1) ES2375585T3 (de)
IL (1) IL200323A (de)
MX (1) MX2009009065A (de)
WO (1) WO2008107334A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5656474B2 (ja) 2010-06-28 2015-01-21 関東化学株式会社 脂肪族光学活性フルオロアルコールの製造方法
CN104628679B (zh) * 2013-11-08 2018-02-09 江苏恩华药业股份有限公司 Bitopertin的合成方法及其中间体
CN106397312B (zh) * 2015-07-31 2020-03-24 广东东阳光药业有限公司 一种制备glyt-1抑制剂的方法
CN115279372A (zh) 2020-01-09 2022-11-01 迪斯克医药公司 用甘氨酸转运蛋白抑制剂治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法
MX2023004293A (es) 2020-10-13 2023-05-03 Boehringer Ingelheim Int Proceso de reelaboracion.
EP4577540A1 (de) 2022-08-24 2025-07-02 Boehringer Ingelheim International GmbH Skalierbares verfahren zur herstellung eines glyt-1-inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992441A (en) * 1972-12-26 1976-11-16 Pfizer Inc. Sulfamylbenzoic acids
US4480102A (en) * 1982-07-23 1984-10-30 The Dow Chemical Company 2,3-Difluoro-5-(trifluoromethyl)pyridine and methods of making and using the same
EP0370560B1 (de) * 1988-11-24 1994-01-12 Akzo Nobel N.V. 1-[Mono- oder bis(trifluormethyl)-2-pyridinyl]piperazine enthaltende pharmazeutische Zusammensetzungen
DE4235155A1 (de) * 1992-10-19 1994-04-21 Basf Ag Verfahren zur Herstellung von Methylsulfonylbenzoesäuren
DE69906059D1 (de) * 1998-04-20 2003-04-24 Fujisawa Pharmaceutical Co Anthranilsäurederivate als inhibitoren der c-gmp-phosphodiesterase
DE10112040A1 (de) 2001-03-14 2002-10-02 Aventis Pharma Gmbh Verbessertes Verfahren zur Herstellung von Sulfonylcarboxamidderivaten
GB0227240D0 (en) * 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
DK1656361T3 (da) * 2003-08-11 2008-05-05 Hoffmann La Roche Piperazin med OR-substitueret phenylgruppe og anvendelse deraf som GLYT1-inhibitorer
SI1828154T1 (sl) * 2004-12-09 2009-08-31 Hoffmann La Roche Derivati fenil-piperazin metanona
CN101356163A (zh) * 2005-01-06 2009-01-28 弗·哈夫曼-拉罗切有限公司 作为甘氨酸转运体1(GlyT-1)抑制剂用于治疗神经学和神经精神病学障碍的硫烷基取代的苯甲酮化合物
DE602005022113D1 (de) * 2005-01-07 2010-08-12 Hoffmann La Roche Phenyl)methanon-derivate als glycin-transporter 1 (glyt-1) hemmer zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
JP4219976B2 (ja) * 2005-07-08 2009-02-04 エフ.ホフマン−ラ ロシュ アーゲー 1,1,1−トリフルオロアセトンの不斉還元

Also Published As

Publication number Publication date
WO2008107334A3 (en) 2008-10-23
WO2008107334A2 (en) 2008-09-12
CA2678630A1 (en) 2008-09-12
BRPI0808570B1 (pt) 2020-09-15
EP2131843A2 (de) 2009-12-16
EP2131843B1 (de) 2011-11-09
BRPI0808570A2 (pt) 2014-09-02
AU2008223915B2 (en) 2013-05-02
AU2008223915A1 (en) 2008-09-12
MX2009009065A (es) 2009-08-31
CA2678630C (en) 2015-04-14
IL200323A0 (en) 2010-04-29
US20080221327A1 (en) 2008-09-11
JP2010520251A (ja) 2010-06-10
BRPI0808570B8 (pt) 2021-05-25
US7812161B2 (en) 2010-10-12
CN101622000B (zh) 2012-07-04
CN101622000A (zh) 2010-01-06
KR101143073B1 (ko) 2012-05-08
IL200323A (en) 2013-11-28
ES2375585T3 (es) 2012-03-02
JP4745446B2 (ja) 2011-08-10
KR20090110368A (ko) 2009-10-21

Similar Documents

Publication Publication Date Title
SI2091948T1 (sl) Novi inhibitorji glutaminil ciklaze
DK2057126T3 (da) Fremgangsmåde til fremstilling af 3-dihalomethyl-pyrazol-4-carboxylsyrederivater
EP2123636A4 (de) Verfahren zur herstellung eines aminoacetylpyrrolidincarbonitrilderivats
ATE477234T1 (de) Synthese von phenolischen estern von hydroxymethylphenolen
GB0412769D0 (en) Organic compounds
ATE532516T1 (de) Verfahren zur synthese von glyt-1-hemmern
CY1112520T1 (el) Βενζυλαμινες, μια διαδικασια για την παραγωγη τους και η χρηση τους ως αντι-φλεγμονωδεις παραγοντες
MX2009013869A (es) Proceso para hacer 2-amino-tiazolonas sustituidas.
BR112013001721A2 (pt) processo de síntese de compostos de ureia substituída
EA200701470A1 (ru) Способы получения производных 4-(фенокси-5-метилпиримидин-4-илокси)пиперидин-1-карбоновой кислоты и родственных соединений
MX2010013758A (es) Procedimiento para elaborar 2-amino-tiazolonas sustituidas.
ATE483679T1 (de) Substituierte cyclohexylessigsäure-derivate
DE602006008962D1 (de) Verfahren zur herstellung von valsartan
WO2008145673A3 (de) Verfahren zur herstellung von 4-formylaminopiperidinderivaten
ATE495158T1 (de) Substituierte tetrahydroisochinoline als mmp- inhibitoren, verfahren zu ihrer herstellung und ihre verwendung als medikament
ATE447567T1 (de) Verfahren zur herstellung von tryptase- inhibitoren
ATE529413T1 (de) Verfahren zur synthese von aryloxydiaminopyrimidinen
DE602007010725D1 (de) Verfahren und zwischenprodukt zur herstellung von donezepil
DE502006003346D1 (de) Verfahren zur herstellung von beta-aminopropionsäurederivaten
DE602006005230D1 (de) Verfahren zur herstellung von 2-azabicycloä3.3.0üoctan-3-carbonsäurederivaten
DE602004008486D1 (de) Verfahren zur herstellung von (1s,4r)-cis-4-ä2-amino-6-chlor-9h-purin-9-ylü-2-cyclopenten-1-methanol
DE502005009501D1 (de) Verfahren zur herstellung von candesartan
ATE469141T1 (de) Verfahren zur herstellung von substituierten thiophensulfonylisocyanaten
DE602007007773D1 (de) Verfahren zur synthese von ibandronat-natrium
ATE444964T1 (de) 5-pyridinyl-1-azabicycloä3.2.1üoctan-derivate, herstellungsverfahren und deren verwendung für therapeutika